There are several possible reasons to explain the failure of first-generation EGFR-TKIs in long-term DFS improvement: (1) the use of first-generation EGFR-TKIs may induce some biological behavior changes in NSCLC patients, resulting in the induction of drug resistance mechanisms [28]; (2) the limited treatment duration of first-generation EGFR-TKIs may be another reason. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.